Mechanisms of disease: Pathogenesis of Crohn's disease and ulcerative colitis

Nature Clinical Practice Gastroenterology and Hepatology

Volumn 3, Issue 7, 2006, Pages 390-407

  Sartor, R Balfour ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Animal models; Bacteria; Crohn's disease; Pathogenesis; Ulcerative colitis

Indexed keywords

ALPHA DEFENSIN; ALUMINUM; ANTIBIOTIC AGENT; AZATHIOPRINE; BACTERIUM LIPOPOLYSACCHARIDE; CASPASE RECRUITMENT DOMAIN PROTEIN 15; CORTICOSTEROID DERIVATIVE; DISCS LARGE HOMOLOG 5 PROTEIN; FLAGELLIN; HEAT SHOCK PROTEIN 60; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLIXIMAB; INTERLEUKIN 12 ANTIBODY; IRON; MERCAPTOPURINE; MULTIDRUG RESISTANCE PROTEIN 1; MURAMYL DIPEPTIDE; NATALIZUMAB; NONSTEROID ANTIINFLAMMATORY AGENT; ORGANIC CATION TRANSPORTER; ORGANIC CATION TRANSPORTER 1; ORGANIC CATION TRANSPORTER 2; ORGANIC CATION TRANSPORTER 4; ORGANIC CATION TRANSPORTER 5; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROBIOTIC AGENT; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; SALAZOSULFAPYRIDINE; SCAFFOLD PROTEIN; TUMOR NECROSIS FACTOR ANTIBODY; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; B LYMPHOCYTE; BACTERIAL INFECTION; BACTERIAL METABOLISM; BACTERIAL TRANSMISSION; BACTERIAL VIRULENCE; BREAST FEEDING; CHROMOSOME 5; CLINICAL TRIAL; CROHN DISEASE; CYTOKINE RELEASE; DENDRITIC CELL; DIET; DISEASE ACTIVITY; DRUG TREATMENT FAILURE; ENTERITIS; ENTEROBACTERIACEAE; ENVIRONMENTAL FACTOR; EPITHELIUM CELL; ESCHERICHIA COLI; EVIDENCE BASED MEDICINE; EXPERIMENTAL ANIMAL; FOOD CONTAMINATION; GENE DELETION; GENE EXPRESSION REGULATION; GENE MUTATION; GENE TARGETING; GENETIC DISORDER; HAPLOTYPE; HOMEOSTASIS; HOST RESISTANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ILEITIS; IMMUNE RESPONSE; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION SENSITIVITY; INNATE IMMUNITY; LISTERIA MONOCYTOGENES; MEDLINE; MYCOBACTERIUM PARATUBERCULOSIS; NATURAL KILLER CELL; NONHUMAN; PANETH CELL; PARATUBERCULOSIS; PATHOGENESIS; PERSISTENT INFECTION; PHENOTYPE; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RECURRENT DISEASE; RELAPSE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; SYSTEMATIC REVIEW; T LYMPHOCYTE; ULCERATIVE COLITIS; ZOONOSIS;

ANIMALS; ANTIBODIES, BACTERIAL; COLITIS, ULCERATIVE; CROHN DISEASE; DISEASE MODELS, ANIMAL; ENTEROBACTERIACEAE; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; INTESTINAL MUCOSA; T-LYMPHOCYTES;

EID: 33745775434     PISSN: 17434378     EISSN: 17434386     Source Type: Journal    
DOI: 10.1038/ncpgasthep0528     Document Type: Review

References (139)

1. Loftus EV Jr (2004) Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology 126: 1504-1517
2. Halfvarson J et al. (2003) Inflammatory bowel disease in a Swedish twin cohort: A long-term follow-up of concordance and clinical characteristics. Gastroenterology 124: 1767-1773
3. Newman B and Siminovitch KA (2005) Recent advances in the genetics of inflammatory bowel disease. Curr Opin Gastroenterol 21: 401-407
4. Schreiber S et al. (2005) Genetics of Crohn disease, an archetypal inflammatory barrier disease. Nat Rev Genet 6: 376-388
5. Hugot JP et al. (2001) Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 411: 599-603
6. Ogura Y et al. (2001) A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 411: 603-606
7. Cario E (2005) Bacterial interactions with cells of the intestinal mucosa: Toll-like receptors and NOD2. Gut 54: 1182-1193
8. Hisamatsu T et al. (2003) CARD15/NOD2 functions as an anti-bacterial factor in human intestinal epithelial cells. Gastroenterology 124: 993-1000
9. Barnich N et al. (2005) GRIM-19 interacts with nucleotide oligomerization domain 2 and serves as downstream effector of anti-bacterial function in intestinal epithelial cells. J Biol Chem 280: 19021-19026
10. Lala S et al. (2003) Crohn's disease and the NOD2 gene: A role for Paneth cells. Gastroenterology 125: 47-57
11. Kobayashi KS et al. (2005) Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract. Science 307: 731-734
12. Wehkamp J et al. (2005) Reduced Paneth cell α-defensins in ileal Crohn's disease. Proc Natl Acad Sci USA 102: 18129-18134
13. Watanabe T et al. (2004) NOD2 is a negative regulator of Toll-like receptor 2-mediated T helper type 1 responses. Nat Immunol 5: 800-808
14. Swidsinski A et al. (2002) Mucosal flora in inflammatory bowel disease. Gastroenterology 122: 44-54
15. Peltekova VD et al. (2004) Functional variants of OCTN cation transporter genes are associated with Crohn disease. Nat Genet 36: 471-475
16. Noble CL et al. (2005) The contribution of OCTN1/2 variants within the IBD5 locus to disease susceptibility and severity in Crohn's disease. Gastroenterology 129: 1854-1864
17. Stoll M et al. (2004) Genetic variation in DLG5 is associated with inflammatory bowel disease. Nat Genet 36: 476-480
18. Ho GT et al. (2005) Allelic variations of the multidrug resistance gene determine susceptibility and disease behavior in ulcerative colitis. Gastroenterology 128: 288-296
19. Brant SR et al. (2003) MDR1 Ala893 polymorphism is associated with inflammatory bowel disease. Am J Hum Genet 73: 1282-1292
20. Farrell RJ et al. (2000) High multidrug resistance (P-glycoprotein 170) expression in inflammatory bowel disease patients who fail medical therapy. Gastroenterology 118: 279-288
21. Panwala CM et al. (1998) A novel model of inflammatory bowel disease: mice deficient for the multiple drug resistance gene, Mdr1a, spontaneously develop colitis. J Immunol 161: 5733-5744
22. Sugawara K et al. (2005) Linkage to peroxisome proliferator-activated receptor-γ in SAMP1/YitFc mice and in human Crohn's disease. Gastroenterology 128: 351-360
23. Dubuquoy L et al. (2003) Impaired expression of peroxisome proliferator-activated receptor γ in ulcerative colitis. Gastroenterology 124: 1265-1276
24. Rousseaux C et al. (2005) Intestinal anti-inflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-γ. J Exp Med 201: 1205-1215
25. Lewis JD et al. (2001) An open-label trial of the PPAR-γ ligand rosiglitazone for active ulcerative colitis. Am J Gastroenterol 96: 3323-3328
26. Su CG et al. (1999) A novel therapy for colitis utilizing PPAR-γ ligands to inhibit the epithelial inflammatory response. J Clin Invest 104: 383-389
27. Duchmann R et al. (1995) Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD). Clin Exp Immunol 102: 448-455
28. Mow WS et al. (2004) Association of antibody responses to microbial antigens and complications of small bowel Crohn's disease. Gastroenterology 126: 414-424
29. Targan SR et al. (1997) A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 337: 1029-1035
30. Mannon PJ et al. (2004) Anti-interleukin-12 antibody for active Crohn's disease. N Engl J Med 351: 2069-2079
31. Sawada K et al. (2005) Leukocytapheresis in ulcerative colitis: Results of a multicenter double-blind prospective case-control study with sham apheresis as placebo treatment. Am J Gastroenterol 100: 1362-1369
32. Lichtiger S et al. (1994) Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 330: 1841-1845
33. Sartor RB and Hoentjen F (2005) Proinflammatory cytokines and signaling pathways in intestinal innate immune cells. In Mucosal Immunology, 681-701 (Eds Mestecky J et al) Philadelphia: Elsevier
34. Reaves TA et al. (2005) Neutrophil transepithelial migration: Role of Toll-like receptors in mucosal inflammation. Mem Inst Oswaldd Cruz 100 (Suppl 1): 191-198
35. Smythies LE et al. (2005) Human intestinal macrophages display profound inflammatory anergy despite avid phagocytic and bacteriocidal activity. J Clin Invest 115: 66-75
36. Iwasaki A and Medzhitov R (2004) Toll-like receptor control of the adaptive immune responses. Nat Immunol 5: 987-995
37. Jarnerot G et al. (2005) Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: A randomized, placebo-controlled study. Gastroenterology 128: 1805-1811
38. Neurath MF et al. (1996) Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF-κB abrogates established experimental colitis in mice. Nat Med 2: 998-1004
39. Egan LJ et al. (2004) IκB-kinaseβ-dependent NF-κB activation provides radioprotection to the intestinal epithelium. Proc Natl Acad Sci USA 101: 2452-2457
40. Chen LW et al. (2003) The two faces of IKK and NF-κB inhibition: prevention of systemic inflammation but increased local injury following intestinal ischemia-reperfusion. Nat Med 9: 575-581
41. Araki A et al. (2005) MyD88-deficient mice develop severe intestinal inflammation in dextran sodium sulfate colitis. J Gastroenterol 40: 16-23
42. Rakoff-Nahoum S et al. (2004) Recognition of commensal microflora by Toll-like receptors is required for intestinal homeostasis. Cell 118: 229-241
43. Sartor RB (2004) Animal models of intestinal inflammation. In Kirsner's Inflammatory Bowel Diseases, 120-137 (Eds Sartor RB and Sandborn WJ) Philadelphia: Elsevier
44. Spencer DM et al. (2002) Distinct inflammatory mechanisms mediate early versus late colitis in mice. Gastroenterology 122: 94-105
45. H2 cytokines in a murine model of chronic small intestinal inflammation. Gastroenterology 128: 654-666
46. Kolls JK and Linden A (2004). Interleukin-17 family members and inflammation. Immunity 21: 467-476
47. Becker C et al. (2003) Constitutive p40 promoter activation and IL-23 production in the terminal ileum mediated by dendritic cells. J Clin Invest 112: 693-706
48. Fujino S et al. (2003) Increased expression of interleukin 17 in inflammatory bowel disease. Gut 52: 65-70
49. Schmidt C et al. (2005) Expression of intedeukin-12-related cytokine transcripts in inflammatory bowel disease: Elevated interleukin-23p19 and interleukin-27p28 in Crohn's disease but not in ulcerative colitis. Inflamm Bowel Dis 11: 16-23
50. Yen D et al. (2006) IL-23 is essential for T-cell mediated colitis and promotes inflammation via IL-17 and IL-6. J Clin Invest 116: 1310-1316
51. Monteleone G et al. (2005) Interleukin-21 enhances T-helper cell type I signaling and interferon-γ production in Crohn's disease. Gastroenterology 128: 687-694
52. Neurath MF et al. (2002) The transcription factor T-bet regulates mucosal T cell activation in experimental colitis and Crohn's disease. J Exp Med 195: 1129-1143
53. + lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-γ, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J Immunol 157: 1261-1270
54. H2 response in ulcerative colitis. J Clin Invest 113: 1490-1497
55. Hart AL et al. (2005) Characteristics of intestinal dendritic cells in inflammatory bowel diseases. Gastroenterology 129: 50-65
56. Totsuka T et al. (2003) Ameliorating effect of anti-inducible co-stimulator monoclonal antibody in a murine model of chronic colitis. Gastroenterology 124: 410-421
57. Williams IR (2004) Chemokine receptors and leukocyte trafficking in the mucosal immune system. Immunol Res 29: 283-292
58. Hosoe N et al. (2004) Demonstration of functional role of TECK/CCL25 in T lymphocyte-endothelium interaction in inflamed and uninflamed intestinal mucosa. Am J Physiol Gastrointest Liver Physiol 286: G458-G466
59. + T lymphocytes are preferentially recruited to the ileum in Crohn's disease. Gut 53: 1287-1294
60. Ghosh S et al. (2003) Natalizumab for active Crohn's disease. N Engl J Med 348: 24-32
61. Feagan BG et al. (2005) Treatment of ulcerative colitis with a humanized antibody to the α4β7 integrin. N Engl J Med 352: 2499-2507
62. Haller D et al. (2002) IKKβ and phosphatidylinositol 3-kinase/Akt participate in non-pathogenic Gram-negative enteric bacteria-induced RelA phosphorylation and NF-κB activation in both primary and intestinal epithelial cell lines. J Biol Chem 277: 38168-38178
63. Ruiz PA et al. (2005) IL-10 gene-deficient mice lack TGF β/Smad signaling and fail to inhibit proinflammatory gene expression in intestinal epithelial cells after the colonization with colitogenic Enterococcus faecalis. J Immunol 174: 2990-2999
64. Lodes MJ et al. (2004) Bacterial flagellin is a dominant antigen in Crohn's disease. J Clin Invest 113: 1296-1306
65. Targan SR et al. (2005) Antibodies to CBir1 flagellin define a unique response that is associated independently with complicated Crohn's disease. Gastroenterology 128: 2020-2028
66. Hoentjen IF et al. (2005) STAT3 regulates NF-κB recruitment to the IL-12 p40 promoter in dendritic cells. Blood 105: 689-696
67. Katakura K et al. (2005) Toll-like receptor 9-induced type I IFN protects mice from experimental colitis. J Clin Invest 115: 695-702
68. Kim SC et al. (2005) Variable phenotypes of enterocolitis in intedeukin 10-deficient mice monoassociated with two different commensal bacteria. Gastroenterology 128: 891-906
69. Sellon RK et al. (1998) Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interieukin-10-deficient mice. Infect Immun 66: 5224-5231
70. Macpherson A et al. (1996) Mucosal antibodies in inflammatory bowel disease are directed against intestinal bacteria. Gut 38: 365-375
71. Brandwein SL et al. (1997) Spontaneously colitic C3H/HeJBir mice demonstrate selective antibody reactivity to antigens of the enteric bacterial flora. J Immunol 159: 44-52
72. Mizoguchi E et al. (1997) Antineutrophil cytoplasmic antibodies in T-cell receptor alpha-deficient mice with chronic colitis. Gastroenterology 113: 1828-1835
73. Mizoguchi A (1997) Suppressive role of B cells in chronic colitis of T cell receptor alpha mutant mice. J Exp Med 186: 1749-1756
74. Velazquez P et al. (2005) Surveillance B lymphocytes and mucosal immunoregulation. Springer Semin Immunopathol 26: 453-462
75. Cong Y et al. (2002) Bacterial-reactive T regulatory cells inhibit pathogenic immune responses to the enteric flora. J Immunol 169: 6112-6119
76. Veltkamp C et al. (2001) Continuous stimulation by normal luminal bacteria is essential for the development and perpetuation of colitis in Tg(ε26) mice. Gastroenterology 120: 900-913
77. Kim SC et al. (2005) Different host genetic backgrounds determine disease phenotypes induced by selective bacterial colonization [abstract]. Gastroenterology 128: A512
78. Bibiloni R et al. (2005) Analysis of the large bowel microbiota of colitic mice using PCR/DGGE. Lett Appl Microbiol 41: 45-51
79. Moran JP et al. (2006) Bifidobacterium animalis causes mild inflammatory bowel disease in interleukin-10 knockout mice [abstract]. Gastroenterology 130: A6
80. Holt L et al. (2005) Heat shock protein (HSP) 60 from Bacteroides vulgatus stimulates proinflammatory cytokine production by rat splenocytes [abstract]. Gastroenterology 128: A512
81. Sartor RB (2004) Microbial influences in inflammatory bowel disease: role in pathogenesis and clinical implications. In Kirsner's Inflammatory Bowel Diseases, 138-162 (Eds Sartor RB and Sandborn WJ) Philadelphia: Elsevier
82. -/- mice with two nonpathogenic commensal bacterial species accelerates colitis [abstract]. Gastroenterology 126: A291
83. -/- mice [abstract]. Gastroenterology 128: A210
84. Dieleman LA et al. (2003) Lactobacillus GG prevents recurrence of colitis in HLA-B27 transgenic rats after antibiotic treatment. Gut 52: 370-376
85. Schultz M et al. (2002) Lactobacillus plantarum 299V in the treatment and prevention of spontaneous colitis in interleukin-10 deficient mice. Inflamm Bowel Dis 8: 71-80
86. Sartor RB (2004) Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: Antibiotics, probiotics and prebiotics. Gastroenterology 126: 1620-1633
87. Bibiloni R et al. (2005) VSL#3 probiotic mixture induces remission in patients with active ulcerative colitis. Am J Gastroenterol 100: 1539-1546
88. Kuisma J et al. (2003) Effect of Lactobacillus rhamnosus GG on ileal pouch inflammation and microbial flora. Aliment Pharmacol Ther 17: 509-515
89. Gionchetti P et al. (2000) Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: A double-blind, placebo-controlled trial. Gastroenterology 119: 305-309
90. Berg DJ et al. (2002) Rapid development of colitis in NSAID-treated IL-10-deficient mice. Gastroenterology 123: 1527-1542
91. Ped DP et al. (2004) Bacterial-metal interactions: The potential role of aluminum and other trace elements in the etiology of Crohn's disease. Inflamm Bowel Dis 10: 881-883
92. Birrenbach T and Bocker U (2004) Inflammatory bowel disease and smoking: a review of epidemiology, pathophysiology, and therapeutic implications. Inflamm Bowel Dis 10: 848-859
93. Cosnes J (2004) Tobacco and IBD: Relevance in the understanding of disease mechanisms and clinical practice. Best Pract Res Clin Gastroenterol 18: 481-496
94. Sartor RB (2005) Does Mycobacterium avium subspecies paratuberculosis cause Crohn's disease? Gut 54: 896-898
95. Chiodini RJ et al. (1984) Possible role of mycobacteria in inflammatory bowel disease. I. An unclassified Mycobacterium species isolated from patients with Crohn's disease. Dig Dis Sci 29: 1073-1079
96. Shafran I et al. (2002) Open clinical trial of rifabutin and clarithromycin therapy in Crohn's disease. Dig Liver Dis 34: 22-28
97. Millar D et al. (1996) IS900 PCR to detect Mycobacterium paratuberculosis in retail supplies of whole pasteurized cows'milk in England and Wales. Appl Env Microbiol 62: 3446-3452
98. Naser SA et al. (2000) Isolation of Mycobacterium avium subsp paratuberculosis from breast milk of Crohn's disease patients. Am J Gastroenterol 95: 1094-1095
99. Naser SA et al. (2004) Culture of Mycobacterium avium subspecies paratuberculosis from the blood of patients with Crohn's disease. Lancet 364: 1039-1044
100. Autschbach F et al. (2005) High prevalence of Mycobacterium avium subsp. paratuberculosis IS900 DNA in gut tissues from individuals with Crohn's disease. Gut 54: 944-999
101. Jubb TF and Galvin JW (2004) Effect of a test and control program for bovine Johne's disease in Victorian dairy herds 1992-2002. Aust Vet J 82: 228-232
102. Raizman EA et al. (2004) The distribution of Mycobacterium avium ssp. paratuberculosis in the environment surrounding Minnesota dairy farms. J Dairy Sci 87: 2959-2966
103. Lund BM et al. (2002) Pasteurization of milk and the heat resistance of Mycobacterium avium subsp. paratuberculosis: A critical review of the data. Int J Food Microbiol 77: 135-145
104. Darfeuille-Michaud A et al. (2004) High prevalence of adherent-invasive Escherichia coll associated with ileal mucosa in Crohn's disease. Gastroenterology 127: 412-421
105. Peeters H et al. CARD15 variants determine a disturbed response of monocytes to adherent-invasive Escherichia coli LF82 in Crohn's disease [abstract]. Ann NY Acad Sci, in press
106. Liu Y et al. (1995) Immunocytochemical evidence of Listeria, Escherichia coli, and Streptococcus antigens in Crohn's disease. Gastroenterology 108: 1396-1404
107. Darfeuille-Michaud A (2002) Adherent-invasive Escherichia coli: A putative new E. coli pathotype associated with Crohn's disease. Int J Med Microbiol 292: 185-193
108. Huycke MM et al. Superoxide production by Enterococcus faecalis upregulates NTN1 oncogene in the colonic epithelium and alters inflammation-associated gene expression [abstract]. Ann NY Acad Sci, in press
109. Erichsen K et al. (2005) Low-dose oral ferrous fumarate aggravated intestinal inflammation in rats with DSS-induced colitis. Inflamm Bowel Dis 11: 744-748
110. Lerner A et al. (2006) Bacterial-aluminum interactions. The role of aluminum in bacterial-induced colitis in IL-10 deficient mice [abstract]. Gastroenterology 130: A362
111. Summers RW et al. (2005) Trichuris suis therapy for active ulcerative colitis: A randomized controlled trial. Gastroenterology 128: 825-832
112. Summers RW et al. (2005) Trichuris suis therapy in Crohn's disease. Gut 54: 87-90
113. Elliott DE et al. (2004) Heligmosomoides polygyrus inhibits established colitis in IL-10-deficient mice. Eur J Immunol 34: 2690-2698
114. Korzenik JR and Dieckgraefe BK (2000) Is Crohn's disease an immunodeficiency? A hypothesis suggesting possible early events in the pathogenesis of Crohn's disease. Dig Dis Sci 45: 1121-1129
115. Korzenik JR et al. (2005) Sargramostim for active Crohn's disease. N Engl J Med 362: 2193-2201
116. Powrie F (2004) Immune regulation in the intestine: A balancing act between effector and regulatory T cell responses. Ann NY Acad Sci 1029: 132-141
117. Elson CO et al. (2004) Gene disruption and immunity in experimental colitis. Inflamm Bowel Dis 10 (Suppl 1): S25-S28
118. Allez M and Mayer L (2004) Regulatory T cells: Peace keepers in the gut. Inflamm Bowel Dis 10: 666-676
119. Bouma G and Strober W (2003). The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol 3: 521-533
120. Fuss IJ et al. (2002) The interrelated roles of TGF-β and IL-10 in the regulation of experimental colitis. J Immunol 168: 900-908
121. Kraus TA et al. (2004) Failure to induce oral tolerance to a soluble protein in patients with inflammatory bowel disease. Gastroenterology 126: 1771-1778
122. Monteleone G et al. (2001) Blocking Smad7 restores TGF-β1 signaling in chronic inflammatory bowel disease. J Clin Invest 108: 601-609
123. + T cells are important for the balance between protective and pathogenic cell-mediated immunity. J Exp Med 179: 589-600
124. + regulatory T cells. J Immunol 170: 3939-3943
125. Albright C et al. (2002) Endogenous IL-10 inhibits APC stimulation of T lymphocyte responses to luminal bacteria [abstract]. Gastroenterology 122: A270
126. + T lymphocytes maintains mucosal homeostasis [abstract]. Gastroenterology 130: A232
127. Maeda S et al. (2005) Nod2 mutation in Crohn's disease potentiates NF-κB activity and IL-1β processing. Science 307: 734-738
128. Rachmilewitz D et al. (2004) Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis. Gastroenterology 126: 520-528
129. Anent S et al. Plasmacytoid DCs are critical elements in the response to GM-CSF in the DSS colitis model [abstract]. Ann NY Acad Sci, in press
130. Beckwith J et al. (2005) Cdcs 1, a major colitogenic locus in mice, regulates innate and adaptive immune response to enteric bacterial antigens. Gastroenterology 129: 1473-1484
131. Itoh J et al. (2001) Decreased Bax expression by mucosal T cells favours resistance to apoptosis in Crohn's disease. Gut 49: 35-41
132. Atreya R et al. (2000) Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: Evidence in Crohn's disease and experimental colitis in vivo. Nat Med 6: 583-588
133. Peppelenbosch MP and van Deventer SJ (2004) T cell apoptosis and inflammatory bowel disease. Gut 53: 1556-1558
134. + T lymphocytes. J Clin Invest 111: 1133-1145
135. Doering J et al. (2004) Induction of T lymphocyte apoptosis by sulphasalazine in patients with Crohn's disease. Gut 53: 1632-1638
136. Lugering A et al. (2001) Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. Gastroenterology 121: 1145-1157
137. ten Hove T et al. (2002) Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut 50: 206-211
138. Van den Brande JM et al. (2003) Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 124: 1774-1785
139. Selby W (2005) Antibiotic therapy for Crohn's disease. Presented at 9th Annual Coolum Update in Gastroenterology and Hepatology: 2005 June 11-13; Coolum